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Abstract
Epilepsy is the most common neurological disorder in dogs, with an incidence ranging from 0.5% to up to 20% in particular
breeds. Canine epilepsy can be etiologically defined as idiopathic or symptomatic. Epileptic seizures may be classified as focal
with or without secondary generalization, or as primary generalized. Nine genes have been identified for symptomatic (storage
diseases) and one for idiopathic epilepsy in different breeds. However, the genetic background of common canine epilepsies
remains unknown. We have studied the clinical and genetic background of epilepsy in Belgian Shepherds. We collected 159
cases and 148 controls and confirmed the presence of epilepsy through epilepsy questionnaires and clinical examinations. The
MRI was normal while interictal EEG revealed abnormalities and variable foci in the clinically examined affected dogs. A
genome-wide association study using Affymetrix 50K SNP arrays in 40 cases and 44 controls mapped the epilepsy locus on
CFA37, which was replicated in an independent cohort (81 cases and 88 controls; combined p=9.70610210, OR=3.3). Fine
mapping study defined a,1 Mb region including 12 genes of which none are known epilepsy genes or encode ion channels.
Exonic sequencing was performed for two candidate genes, KLF7 and ADAM23. No variation was found in KLF7 but a highly-
associated non-synonymous variant, G1203A (R387H) was present in the ADAM23 gene (p= 3.761028, OR= 3.9 for
homozygosity). Homozygosity for a two-SNP haplotype within the ADAM23 gene conferred the highest risk for epilepsy
(p= 6.28610211, OR=7.4). ADAM23 interacts with known epilepsy proteins LGI1 and LGI2. However, our data suggests that
the ADAM23 variant is a polymorphism and we have initiated a targeted re-sequencing study across the locus to identify the
causative mutation. It would establish the affected breed as a novel therapeutic model, help to develop a DNA test for
breeding purposes and introduce a novel candidate gene for human idiopathic epilepsies.
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Introduction
Epilepsy is one of the most common neurological diseases
affecting 1–3% of the human population [1]. Epilepsy refers to
a group of chronic neurological symptoms characterized by
recurrent unprovoked seizures. Seizures are transient symptoms
of abnormal, excessive or synchronous neuronal activity in the
brain and can be classified into two major types: focal-onset and
primarily generalized. In focal-onset seizures, the synchronized
activity is restricted to a single part of the cortex, and may or may
not subsequently spread to recruit the thalamocortical pathways
and result in secondary generalization. Focal motor seizures may
be characterized by elementary motor events, which consist of a
single type of stereotyped contraction of a muscle or group of
muscles or by autonomic features or paroxysms of behavioral signs
probably corresponding to disturbance of higher cerebral activity
in humans known as psychic seizures [2]. In generalized seizures,
the thalamocortical circuitry is involved in the attack and results in
synchronized firing of neurons brain-wide, unconsciousness and
often tonic-clonic seizures. In humans, epileptic syndromes are
defined by such phenotypic criteria as age of onset, survival, type
of electroencephalographic (EEG) abnormalities, seizure charac-
teristics, and the type of stimulus that induces seizures [3–7]. A
majority of epilepsies have a suspected polygenic background.
However, only a few risk genes are known to date, and a large
number of genes contributing to human epilepsy still remain to be
identified [8].
Epilepsy is also the most common chronic neurological disorder
in dogs, and has been identified by breeders as one of the top three
diseases of concern. Canine epilepsy can be classified either as
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idiopathic (genetic) or symptomatic (structural/metabolic) accord-
ing to recent ILAE recommendations in humans [9]. Epileptic
seizures are classified according to initial clinical signs either as
focal or generalized seizures [9,10]. Additionally, focal seizures
may become secondarily generalized.
The prevalence of epilepsy in purebred dogs is estimated to
range from 0.5% to 1%. However, in some breeds there is a strong
suspicion of an underlying genetic factor as there is an
accumulation of epileptic individuals within families with an
incidence as high as 20% [4,11–18]. Moreover, the majority of the
pedigree studies suggest a polygenic mode of inheritance.
Genetic homogeneity within dog breeds and heterogeneity
across breeds, together with the recent advent of genome-wide
mapping tools with high resolution provide a powerful approach
for gene mapping of both simple and complex traits in dogs [19–
22]. Naturally occurring spontaneous canine epilepsies resemble
clinically human epilepsies and provide exciting models to further
understand the genetics and the etiopathologies of seizure dis-
orders. The first canine symptomatic epilepsy gene, NHLRC1, was
found in the Miniature Wirehaired Dachshund presenting canine
Lafora disease [23]. This was followed by eight genes related to
particular forms of neuronal ceroid lipofuscinoses (NCLs) [24–31].
Most of these known canine progressive myoclonus epilepsy (PME)
genes are orthologues of the corresponding human syndromes and
two new NCL candidate genes, ARSG and ATP13A2, have been
identified for human NCLs [24,27].
The first canine IE mutation in the LGI2 gene was recently
identified in Lagotto Romagnolo dogs with focal remitting juvenile
epilepsy [32,33]. Despite efforts using either candidate gene [34]
or low-resolution genome wide approaches [35,36], the genetic
background of many focal and generalized epilepsies remains
largely unknown.
As part of our larger ongoing program to tackle the genetics of
canine epilepsies (www.eurolupa.org), we have developed further
resources to map the IE genes in Belgian Shepherds (BS) suffering
from epilepsy dominated by focal seizures with or without
secondary generalization [18]. Epileptic seizures vary from mild
to intractable and typically have an onset around 3 years of age in
this breed [18,37]. Various pedigree analyses have suggested
different modes of inheritance from simple recessive to polygenic
with a major gene or a gene with incomplete penetrance
[7,18,35,36]. A recent microsatellite-based genome wide linkage
scan with 366 dogs including 74 cases identified six tentative loci
on four chromosomes, although none of them reached a genome-
wide significance [36]. This could indicate genetic or phenotypic
heterogeneity of epilepsy in BS. However, due to lack of power
and resolution these results are not conclusive.
We have performed clinical characterizations including EEG
recordings and a high-resolution genome-wide association study
(GWAS) in a case-control cohort of BS dogs to identify IE loci. We
successfully mapped a locus at CFA37 and defined a ,1 Mb
region containing novel candidate IE genes. This study establishes
the first locus for the most common forms of seizures in dogs.
Results
Summary of the epilepsy cases collected for the
investigation
To identify the genetic cause of IE in Belgian Shepherds (BS) we
collected altogether 307 samples including 159 cases and 148
controls collected in Finland, Denmark and USA. Characterization
of the Finnish study cohort was based on clinical examination of
selected dogs and analysis of the owner-filled epilepsy questionnaires.
To describe the Finnish cohort we analyzed 94 questionnaires from
epileptic dogs as summarized in the Table S1. The vast majority of
the dogs with only questionnaire data (78%) had also been diagnosed
with epilepsy by a practicing veterinarian. The epileptic dogs showed
a highly variable age of onset ranging from 3 months to 9 years with
a mean at 3.3 years. The median seizure frequency was 5.25 per year
with some dogs having less than one seizure per year and others
having up to 10 seizures per day. The epileptic dogs had experienced
on average 10 seizures (range 2–100) and one third presented
clustered seizures (more than one seizure in a day). The typical
duration of seizure was 2–4 minutes although ranging from 0.5–
60 min. Almost half of the owners (42.7%) were able to identify
phenomenology preceding convulsions as a sign of focal seizure
activity. The typical clinical signs included restlessness, seeking of the
owner’s attention, drooling and nausea, which suggest a focal onset.
Secondary generalization of focal seizures was commonly charac-
terized by stiffening of limbs and neck, muscle fasciculation, tremor,
drooling, staring, falling, tonic-clonic convulsions and urination. One
third of the dogs did not react to owners’ calls indicating a severely
impaired consciousness. Postictal recovery time varied from minutes
to hours.
The seizure types of the dogs were defined based on the seizure
description. The majority of the dogs (37%) showed focal seizures
with secondary generalization, one third of the dogs (34%) showed
generalized seizures with unknown onset, 18% showed primarily
generalized seizures and 7% of the dogs seizures were focal
without secondary generalization. The seizure type of three dogs
remained unclassified.
In the Finnish study cohort, 48 dogs out of 94 dogs (51%) were
on anti-epileptic medication. Based on the 33 response reports,
anti-epileptic medication was effective and prevented seizures in
18 (55%), halved the frequency in 10 (30%) and decreased it in 4
dogs (12%). Only one dog (3%) did not respond to medication.
Seizure medication consisted mainly of Phenobarbital (88%) or
potassium bromide (10%).
Clinical studies
Clinical examinations were performed on 17 Finnish cases and 4
controls (Table 1). All examined dogs were normal with regards to
neurological examination, MRI, blood and CSF tests. These results
exclude possible external causes of epilepsy and further support the
presence of IE in the breed. At the visual examination of the EEG
recordings, all dogs exhibited high-voltage low-frequency back-
ground activity. Background activity was superimposed with
spindles or focal beta bursts in control dogs and in 2 dogs with
epilepsy (dog 4 and dog 9). The standard descriptions used in
human neurophysiology were adapted to describe all the EEG
patterns [38]. Paroxysmal activity was observed in epileptic dogs,
and it was characterized by sharp waves, spikes, and spike-and-slow-
wave complexes in variable derivations (Table 1, Fig. 1). Two of
the dogs exhibited midline spikes (dog 30 and dog 33), one had
volley of sharp waves in centro-temporal-posterior right derivations
(dog 9) and the other epileptic dogs exhibited spikes and spike-and-
wave complexes in variable derivations. BETS and sleep spindles in
healthy and epileptic dogs under medetomidine sedation were
described previously [39]. Beta bursts are very similar to sleep
spindles. They differ in having higher frequency, longer duration,
and do not begin and end abruptly [40]. Both of these transients
occur in the frontal, central, and parietal derivations. In humans,
midline spike is supposed to represent epileptiform activity of
uncertain clinical relevance [41,42]. Spikes and spike-and-slow-
wave complexes are considered as specific findings in many human
epileptic syndromes [42,43]. These findings were the only interictal
abnormal EEG patterns detected in the dogs with epilepsy,
suggesting a variable focal paroxysmal discharge.
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The Danish epilepsy cases were investigated with interview
questionnaires, clinical and neurological examination and para-
clinical tests and has been characterized with respect to clinical
epilepsy phenotype and semiology reported in previous publica-
tions [7,18]. In general the clinical epilepsy phenotype displayed
by the Finnish and the Danish cohorts were similar.
GWAS, replication and fine mapping
To map the epilepsy genes we performed a GWAS with 40
cases and 44 seizure-free controls (27 cases and 27 controls from
Finland and 13 cases and 17 controls from Denmark). The
controls were .7 years old and country- and variant-matched to
the cases. A significant association was detected around SNPs on
CFA37 with the best SNP BICF2P890779 at 18,123,961 bp
(praw= 1.3610
26, pgenome = 0.017) (Fig. 2A). Other putative loci
were found on chromosomes 3, 4, 9, 18, and 23 although not at a
genome-wide significant level (Fig. 2A).
As a replication study we genotyped the SNP BICF2P890779
showing the strongest association with IE at CFA37 in an
independent sample cohort of 81 cases and 88 controls
(p = 3.761025, OR=2.6, 95% CI 1.6–4.1). A combined analysis
of all genotyped samples including the original GWAS and the
replication cohorts yielded a p-value of 9.7610210 and OR=3.3
(95% CI 2.2–4.9) (Table 2). Homozygosity with respect to the
allele A increased the risk of epilepsy by 5.4-fold (95% CI 3.1–9.3,
p = 6.8610210). The frequency of the AA genotype was 0.62
among cases and 0.24 among controls. The nominal association
signals on chromosomes 3, 4, 9, 18, and 23 were followed up by
replication of the best-associated SNPs in each locus using 54 cases
and 62 controls. None of these loci showed evidence for
association in the replication cohort (Table 2).
To fine map the associated locus we genotyped 83 BS cases and
99 BS controls with 96 SNPs from a 8.3 Mb region at CFA37
(12,660,614–20,989,289 bp). Fine mapping defined a ,1 Mb
region with the strongest association to a SNP BICF2P890779 at
18,123,961 bp (praw= 6.6610
28, p10006perm= 1.0610
23) (Fig. 2B).
Candidate gene sequencing
The associated 1 Mb region at CFA37 contains 12 genes of
which two, ADAM23 and KLF7, have functions in neuronal
systems (Fig. 2C). Mutations in ADAM23 have not been found in
epileptic patients, but it interacts with LGI1, a gene associated with
familial temporal lobe epilepsy-1 (ETL1) in human [44] and with
LGI2, which is the causative gene for benign focal epilepsy in dogs
Table 1. Summary of clinical examinations performed on 17 epileptic and 4 healthy Finnish BS dogs.
Dog
ID
variation/
sex age
age of
seizure
onset
overall
clinical
examination
neurologic
examination
blood
chemistry MRI CSF
EEG
activity
Regions where
EEG activity
were detected
Seizure type
based on
questionnaire1 diagnosis2
Dog 4 ter/female 13 y 2 y norm norm norm norm norm focal Left anterior
derivations
CFG IE
Dog 6 gro/male 6 y 5,5 y norm norm norm norm norm NA CFG IE
Dog 7 gro/female 4 y 3 y norm norm norm norm norm NA CFG IE
Dog 8 gro/male 6 y 2 y norm norm norm norm norm NA CF IE
Dog 9 gro/female 7 y 3 y norm norm norm norm norm focal Central (entire
right hemisphere)
CFG IE
Dog 11 gro/female 8 y 7 y norm norm norm norm norm NA CFG IE
Dog 12 gro/female 6 y 5 y norm norm norm norm norm NA CFG IE
Dog 13 gro/female 4 y 3 y norm norm norm norm norm focal Right temporal
posterior
derivations
CFG IE
Dog 17 ter/male 5 y 2,5 y norm norm norm norm norm NA CFG IE
Dog 18 ter/female 4 y 0,5 y norm norm norm norm norm NA CFG IE
Dog 20 ter/male 8 y 5 y norm norm norm norm norm NA GUO IE
Dog 22 ter/male 3 y 2,5 y norm norm norm norm norm focal Right and left
posterior
derivations
CFG IE
Dog 26 ter/female 3 y 2 y norm norm norm norm norm focal Right central
and posterior
derivations
CFG IE
Dog 27 ter/male 3 y 2 y norm norm norm norm norm NA CFG IE
Dog 30 ter/female 4 y 2,5 y norm norm norm norm norm focal Midline CF IE
Dog 33 gro/female 5 y 1,5 y norm norm norm norm norm focal Midline CFG IE
Dog 34 gro/male 6 y 3,5 y norm norm norm norm norm NA NA IE
Dog 1C ter/female 3,8 y norm norm norm norm norm NA healthy
Dog 2C ter/male 6,9 y norm norm norm norm norm NA healthy
Dog 3C mal/female 7,5 y norm norm norm norm norm NA healthy
Dog 4C gro/female 6,3 y norm norm norm norm norm norm healthy
1CFG= complex focal generalized, CF = complex focal, GUO=generalized with unknown onset, NA= not available.
2IE = idiopathic epilepsy.
doi:10.1371/journal.pone.0033549.t001
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[33]. KLF7 is a neuronal transcription factor, which is required for
neuronal morphogenesis and axon guidance in selected regions of
the brain [45]. Sequence analysis of KLF7 did not reveal any
coding variants. Screening of the ADAM23 exons revealed a non-
synonymous variant in exon 12 (G1203A according to predicted
mRNA XM_844759) at 18,113,688 bp causing an amino acid
change (R387H according to XP_849852.1) in four affected dogs.
To further investigate the frequency of the variant, we genotyped a
total of 159 cases and 148 controls. The risk allele A frequency was
72% in the cases compared to 49% in the controls (p = 3.161029,
OR=2.7, 95% CI: 1.9–3.8). Homozygosity for the A allele
increased the risk (p = 3.761028, OR=3.9, 95% CI: 2.4–6.4).
However, 22% of controls were also homozygous. Comparison of
frequency of the R387H variant in different epilepsy types did not
show enrichment to specific seizures (data not shown). This
variation was also screened in three epileptic dogs from 38 other
breeds (altogether 114 epileptic dogs), and we found that the
homozygous AA genotype was present in some of the three
affected dogs in altogether 12 breeds (19% of tested dogs) (Barbet,
Beagle, Border Collie, Dachshund, Dalmatian, Golden Retriever,
Irish Water Spaniel, Miniature Pinscher, Petit Basset Griffon
Vendeen, Miniature Poodle, Rottweiler and Whippet). In 15
breeds, the risk allele was present in heterozygous form in some of
the individuals (32%). Furthermore, Panther and PolyPhen-2
programs predicted that R387H is not pathogenic. Overall, these
results suggest that the observed variation is not a causative
mutation but rather a polymorphism, which is likely in the vicinity
of the actual predisposing mutation. Indeed, we identified the
highest risk of epilepsy among individuals homozygous for the
haplotype composed of the risk-conferring alleles of the G1203A
and BICF2P890779 variants (p = 6.28610211 OR=7.4, 95% CI:
3.9–14.0) which are in strong linkage disequilibrium (LD) with
each other (D9=0.87). This suggests that the functional variant lies
within this haplotype block but is neither one of the two SNPs.
We investigated ADAM23 as a candidate gene also through
RNA expression studies. Expression level of ADAM23 was
compared between three healthy and three epileptic Belgian
Shepherds from Denmark. All dogs were clinically examined. A
difference in expression level between the two groups of dogs was
not observed.
Association of the CFA37 locus in other IE breeds
As part of our ongoing clinical and genetic studies on epilepsies,
we have established well-characterized sample cohorts for many
breeds presenting IE. To test whether the identified epilepsy locus
at CFA37 associates with epilepsy in other breeds, we genotyped
the best associated BS SNP (BICF2P890779) in an epilepsy cohort
of 303 cases and 316 controls including samples from Lagotto
Romagnolo, Miniature Pinscher, Kromfohrla¨nder, Whippet,
Border Terrier, Schipperke, Finnish Spitz and Finnish Lapphund
(Table 3). Almost all tested Finnish Spitz and Schipperke dogs
were homozygous for the A-allele and therefore no association
could be calculated in these two breeds. Kromfohrla¨nders
(p = 0.003) and Whippets (p = 0.02) showed a tentative association
(Table 3). These results in both breeds need to be confirmed in a
larger sample cohort with additional markers before further
conclusions.
Discussion
We describe here the second IE locus in dogs. A locus at CFA37
predisposes Belgian Shepherds to focal epilepsy with seizures
originating from multiple cerebral lobes and without any
detectable cerebral lesions on MRI studies. The first canine IE
mutation was described in the Lagotto Romagnolos. This
mutation causes a breed-specific focal epilepsy with remission
[33], whereas BS dogs suffer from seizures that are commonly seen
across breeds. Therefore our results may suggest a genetic locus for
the most common forms of IE in dogs.
The clinically examined BS dogs had normal blood biochem-
istry, CSF, MRI and neurological examination and symptomatic
epilepsy and seizures of extracranial origin was therefore not
suspected. In the cases where interictal EEG was performed we
detected paroxysmal activity originating from different cerebral
lobes. The most common seizure type was a focal-onset with
secondary generalization. The seizures in the minority of the dogs
remained focal and some dogs had primarily generalized seizures.
The fact that only half of the affected dogs received anti-epileptic
medication suggests that epilepsy in the BS has a relatively mild
course. Our study cohort included samples from several countries
including a previously described cohort from Denmark [7,18].
The onset and clinical features in different populations are similar.
There are some differences in proportion of seizure types which
may arise from the fact that a focal seizure onset may be
challenging to observe and describe retrospectively by the owners.
This is most likely the explanation why seizure distributions differ
in the Danish and Finnish cohorts.
The CFA37 locus identified in this study is syntenic with the
region on human chromosome 2q33 (206.8–208.2 Mb). Overlap-
ping interstitial deletions in 2q24–31 have been described in many
human epilepsies often associated with other developmental
defects [46]. Our locus is close to these deletions but not syntenic.
In addition, our clinical characterizations indicate that epileptic
BS dogs present only a seizure disorder without developmental
abnormalities. Another type of human epilepsy called familial
partial epilepsy with variable foci (FPEVF) has also been mapped
to 2q [47]. FPEVF is an autosomal dominant epilepsy with
incomplete penetrance and characterized by epileptic seizures
originating from different cerebral lobes [47,48]. Affected
individuals respond well to antiepileptic drugs and have no brain
lesions. Causative mutations have not been found for FPEVF [47–
51]. Although the clinical features in our dogs resemble the
characteristics of human FPEVF, the most significant region in
dogs is ,10 Mb from the strongest association signal in human
patients. Besides human, an overlapping epilepsy region has been
found in WAG/Rij rats representing a model for human
childhood absence epilepsy [52]. However, the syntenic region
in rats covers an extensive region of the chromosome with many
possible candidate genes.
Previous epidemiological studies have demonstrated a high
prevalence of IE in the BS breed and various inheritance models
have been suggested [7,18,35–37]. We found a major locus at
CFA37 overlapping a previous tentative QTL [36], but with only
a modest disease risk suggesting that still other susceptibility loci
exist. Alternatively, the mildest focal seizures may have been
missed and it is therefore possible that some controls are actually
Figure 1. An example of interictal EEG recording for an epileptic (A) and for a healthy (B) BS dog. The epileptic and healthy dogs
correspond to dogs 26 and 4C in Table 1, respectively. The Epileptic dog shows spike and slow waves in right central and posterior derivations. The
control dog exhibits a high-voltage low-frequency background activity. Background activity is superimposed with focal beta bursts in frontal
derivation. The EEG pattern is consistent with the sedation protocol used. Bipolar montage, time constant = 0.3 s; high filter 70 Hz; notch filter
inserted.
doi:10.1371/journal.pone.0033549.g001
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cases, which would result in the underestimation of the disease
risk. This assumption is supported by a genealogical study
performed in an extended family of dogs investigated over several
years [7]. Our GWAS was performed in a relatively small sample
cohort and with the older version of SNP chip arrays including
,50,000 markers. It is possible that additional loci could be dis-
covered with a larger sample size and higher resolution available
today.
The 1 Mb region showing the strongest association includes 12
genes of which none encode ion channels commonly mutated in
human IEs or other known epilepsy genes [53]. We screened two
genes, ADAM23 and KLF7 for coding and splice site mutations.
ADAM23 represents an excellent candidate gene. It encodes amember
of the disintegrin and metalloprotease domain (ADAM) family and
belongs to a neuronal subfamily of ADAMs together with ADAM22
and ADAM11 [54]. ADAM23 binds two epilepsy-associated proteins,
Figure 2. A genome-wide association study reveals a locus at CFA37. Genomic control –adjusted p-values are shown (A). Fine-mapping of a
8.3 Mb region with 96 additional SNPs on chromosome 37 defines a 1 Mb associated region (B). The region showing strongest association with
epilepsy (17,525,804–18,623,591 bp) contains 12 genes including two neuronal candidates, ADAM23 and KLF7 (C).
doi:10.1371/journal.pone.0033549.g002
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LGI1 and LGI2. LGI1 is mutated in familial temporal lobe epilepsy-
1 (ETL1) in humans, and LGI2 is mutated in benign familial juvenile
epilepsy (BFJE) in Lagotto Romagnolo dogs [33,44]. The truncating
mutations of LGI1 or LGI2 prevent their secretion and interaction
with the ADAM23 complexes. The LGI1-ADAM23 complex is
involved in the stimulation of neurite outgrowth and dendritic
arborisation [55]. ADAM23 containing complex plays a role in
pulling together both pre- and post-synaptic membranes, stabilizing
and strengthening synaptic neurotransmission [56]. Furthermore,
homozygous removal of Adam23 from mice results in a seizure
disorder and even heterozygous mice have lowered seizure
thresholds [56]. We identified only a single non-synonymous
variant from ADAM23 gene, R387H, which is in strong LD with
the associated intronic marker identified in the GWAS. The coding
variant is highly associated and increases the epilepsy risk by 4-fold.
However, given that the homozygous risk allele is common (22%) in
controls, present frequently in 27 other breeds, and unlikely
pathogenic, these results suggest that it is a polymorphism rather
than a causative mutation. Based on our haplotype association
analysis, the causative mutation is likely located in the same
haplotype block tagged by these two variants. The fact that there
were no changes in the expression of ADAM23 in epileptic dogs
suggests that the possible disease causing variant, if present in
ADAM23 at all, does not affect its transcript levels in the brain.
KLF7 belongs to a large family of KLF transcription factors.
KLF7 is the only family member with a neuronally restricted
expression during development. KLF7 is required for neuronal
morphogenesis and axon guidance in hippocampus, olfactory
bulbs and cortex [45,57]. We could not find any variants in the
coding regions of KLF7. The identified locus contains also three
other candidate genes, DYTN, NDUFS1 and FASTKD2, that
function in the CNS or have been associated with neuronal
phenotypes. DYTN is poorly characterized but expressed in the
CNS [58]. NDUFS1 is a core component of the mitochondrial
complex I system, and mutations in this system has been associated
with neurodegenerative disorders [59]. FASTKD2 is a cytochrome
oxidase deficiency related gene and its mutations cause various
neurological phenotypes including convulsions [60]. However, the
phenotypes related to the latter two mitochondrial genes or
systems are not restricted to CNS but affect other organs as well.
There are several possibilities where the actual predisposing
mutation may be located. First, mutation may still lie in the
regulatory regions of the ADAM23 or KLF7 genes. Second,
mutation is present in the other candidate genes not screened yet.
Third, we focused here only on the 1 Mb region showing strongest
association, while our genotype data indicates a remarkable signal
outside the most significant locus. This ,2 Mb region contains
also several candidate genes. To identify the causative variant we
Table 2. The summary of the results in GWAS, replication and combined datasets.
GWA1 Replication2 Combined3
Chromo-
some SNP Position F_A4 F_U5 Praw PGC Pgenome OR F_A
4 F_U5 Praw OR F_A
4 F_U5 Praw OR
3 BICF2P397912 82766251 0.60 0.33 3.91E-4 0.001 0.96 3.11 0.49 0.40 0.14 1.41 0.51 0.39 0.014 1.65
4 TIGRP2P58276 13088720 0.43 0.16 1.39E-4 5.25E-4 0.76 3.91 0.39 0.29 0.07 1.55 0.40 0.26 0.004 1.86
9 BICF2P1288768 18597315 0.43 0.47 4.71E-4 0.001 0.98 0.31 0.43 0.47 0.53 0.86 0.38 0.47 0.078 0.69
18 TIGRP2P239410 15846321 0.15 0.47 1.68E-5 8.95E-5 0.18 0.21 0.30 0.39 0.10 0.67 0.27 0.43 0.001 0.49
23 BICF2G630382382 22138085 0.20 0.48 1.60E-4 5.91E-4 0.79 0.27 0.25 0.31 0.22 0.73 0.24 0.37 0.005 0.53
37 BICF2P890779 18123961 0.53 0.18 1.34E-6 1.09E-5 0.02 5.41 0.72 0.50 3.72E-05 2.59 0.76 0.49 9.70E-10 3.29
1GWAS dataset: 40 cases, 44 controls.
2Replication dataset: chromosomes 3, 4, 9, 18, 23: 54 cases, 62 controls; chromosome 37: 81 cases, 88 controls.
3Combined dataset: chromosomes 3, 4, 9, 18, 23: 94 cases, 106 controls; chromosome 37: 116 cases, 130 controls.
4Frequency of the minor allele (based on GWAS controls) in affected individuals.
5Frequency of the minor allele (based on GWAS controls) in unaffected individuals.
doi:10.1371/journal.pone.0033549.t002
Table 3. Association of ADAM23 intronic SNP (BICF2P890779 at 18,123,961 bp) with epilepsy in 9 different breeds.
Breed N cases+N controls F_A1 (allele A) F_U2 (allele A) P OR
Belgian Shepherd 116+130 0.76 0.49 9.70E-10 3.3
Kromfohrla¨nder 23+18 0.93 0.67 3.44E-03 6.5
Whippet 24+26 0.81 0.60 0.018 2.9
Finnish Spitz 62+81 1.00 0.98 0.13 NA
Lagotto Romagnolo 23+23 0.35 0.48 0.20 0.6
Miniature Pinscher 22+20 0.89 0.80 0.27 2.0
Border Terrier 42+40 0.93 0.89 0.36 1.6
Schipperke 63+48 0.99 1.00 0.38 NA
Finnish Lapphund 44+60 0.79 0.82 0.58 0.8
1Frequency of the minor allele (based on GWAS controls) in affected individuals.
2Frequency of the minor allele (based on GWAS controls) in unaffected individuals.
Frequencies of allele A are shown for each breed. P-values,0.05 are bolded.
doi:10.1371/journal.pone.0033549.t003
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have initiated a targeted re-sequencing project to capture a 4 Mb
locus on CFA37.
As part of our larger canine epilepsy research program we have
collected samples from IE dogs in several breeds. To test the
association of the CFA37 locus in other breeds, we screened the
ADAM23 intronic variant in eight additional breeds. We used
Lagotto Romagnolos as a control breed in the study since we
recently identified the causative mutation in the LGI2 gene on
CFA3 [33]. Our across breed analysis found some evidence for
association in Kromfohrla¨nder and Whippet breeds. However, a
single marker association in a small sample cohort should be
interpreted cautiously and confirmed with replication using more
samples and markers.
The high prevalence of IE among BS dogs causes a severe
health issue in the breed [37]. Although many dogs respond well to
treatments, still almost every fifth epileptic dog is euthanized
within three years after the onset [18]. There is a clear need for
genetic counseling and for the development of marker-assisted
breeding programs. Our study identifies a significant risk allele for
IE. However, since the majority (75%) of the unaffected dogs also
carries one or two copies of the risk allele, it cannot be used for
efficient diagnostics. The identification of the causative mutation
remains as an important task to improve breeding plans, to reveal
a new candidate gene for human IEs, to identify novel IE
pathways, and to establish the breed as a large therapeutic animal
model for IEs. This study makes a breakthrough by mapping a
novel IE locus and paves the way towards the discovery of the first
mutation in the most common seizure type in dogs.
Materials and Methods
Study cohort
A cohort of Belgian Shepherd dogs including 159 epileptic cases
and 148 unaffected controls collected in Finland (178 dogs),
Denmark (65 dogs) and USA (64 dogs) was used in this study.
The Finnish cohort included mainly Finnish dogs (64%) but also
dogs from Sweden, Poland, Australia, Switzerland, Austria,
Germany and the Netherlands. The Danish cohort has been
described previously by Berendt et al. [7,18] and the US cohort by
Oberbauer et al. [35,36] and the Finnish cohort in this paper
(Table 1, Table S1). All study cohorts were collected through Breed
Clubs, breeders and owners and epilepsy diagnoses were based on
questionnaires, telephone interviews and clinical, neurological and
para-clinical examinations on selection of dogs. The clinical char-
acterization of the Finnish cohort was based on clinical examina-
tion on 17 affected dogs and 4 healthy controls from Finland
and detailed owner-filled epilepsy questionnaires from 94 dogs
(http://koirangeenit.fi/Tiedostot/EpilepsyQuestionnaire.doc). Ep-
ilepsy questionnaire requested information about the age of onset,
the number, duration and frequency of seizures, anti-epileptic
medication, and typical characteristics of the ictal, pre- and post-
ictal phases of seizures.
Inclusion criteria for the case in all cohorts required that the dog
had experienced at least two seizures. The age of onset was
reported by the owners and was not used as exclusion criterion due
to possible inaccuracies. The average age of onset was between 3.1
to 4.1 years in different cohorts (ranging from 3 months to 9 years
in the Finnish cohort, from 1.5 years to 11 years in the Danish
cohort and from 2 years to 5 years in the US cohort). None of the
epileptic dogs were known to be affected by other diseases. The
control dogs had no history of seizures and were over 7 years of
age in all cohorts.
The cohort in the GWAS included selected dogs from the
Finnish and Danish cohorts. The GWAS cohort did not include
first degree relatives. The replication cohort was independent from
GWAS and included samples collected in Finland, Denmark and
USA. Fine mapping cohort contains samples collected in Finland
and Denmark. It includes the GWAS samples and overlaps with
replication study cohort (50 cases and 59 controls of the fine
mapping study were included in the replication). The controls
were matched to the cases according to country of origin and
breed variant.
The Finnish Kennel Club’s breeding database, KoiraNet, was
utilized for Finnish pedigrees. EDTA-blood samples were collected
for each dog with the owner’s consent in the genetic analyses and
genomic DNA was extracted using a commercially available kit
(Puregene, Gentra Systems, Minneapolis, MN). We have a valid
ethical permit (ESLH-2009-07827/Ym-23, expiring Oct 2012).
Clinical studies
Clinical studies included clinical and neurological examination,
blood and in selected cases CSF, MRI, EEG tests and were
performed at the Referral Animal Neurology Hospital Aisti,
Vantaa, Finland and Department of Small Animal Clinical
Sciences, University of Copenhagen, Denmark. Blood examina-
tion included complete blood count and serum biochemistry
(sodium, potassium, calcium, phosphorus, magnesium, glucose,
total protein, albumin, globulin, cholesterol, blood urea nitrogen,
creatinine, total bilirubin, alanine aminotransferase, aspartate
aminotransferase, alkaline phosphatase, and creatine kinase). MRI
examinations of Finnish dogs were performed as described
previously [61]. CSF samples were collected from the cerebello-
medullary cistern after MRI examination. Total cell count,
cytology and protein concentration were evaluated.
EEG in Finnish dogs was performed under medetomidine
sedation (0.04 mg/kg IM). An additional 0.02 mg/kg of medeto-
midine was given IM if the dog was not ready for examination
15 minutes after the initial injection. EEG examinations were
performed in a quiet, darkened room. Dogs were placed in sternal
recumbency and electrodes were placed transcutaneously in a
14 channel montage, modified from a 17-channel montage as
described previously [62]. To assure good electrical contact with the
electrodes, the scalp was defatted by rubbing vigorously with ethyl
alcohol. Referential and bipolar montages (F7, F3, F4, F8, T3, C3,
Cz, C4, T4, P3, Pz, P4, O1, O2 ;F4-C4, C4-T4, T4-P4, P4-O2, F3-
C3, C3-T3, T3-P3, P3-O1, F4-F8, F8-T4, F3-F7, F7-T3, Cz-Pz,
O2-Pz, Pz-O1; odd number= left hemisphere; even number= right
hemisphere) were used. The acquisition parameters to record bio-
electrical activity were set as follows: sensitivity= 5 mV/mm; time
constant = 0.3 s; high filter (Hf) = 70 Hz; notch filter inserted;
reference: on the bridge of the nose; ground: caudally to the
external occipital protuberance; electrode impedance ,3 KV;
sampling rate 256 Hz. Sixteen EEG needles (thirty-gauge 15 mm
monopolar stainless steel needle electrodes, Bionen S.a.S., Italy)
were used as active, reference, and ground electrodes. No local
infiltration of lidocaine was performed around electrode placement
sites. Electrocardiogram and respiratory rates were recorded via
polygraphic electrodes (EKG: sensitivity = 70 mV/mm, time con-
stant = 0.1 s, Hf= 30 Hz; respiration - CHEST - : sensitivity =
20 mV/mm, time constant = 0.3 s, Hf= 30 Hz) connected to
alligator clips (thin cable for bridge electrode, Bionen S.a.S.,
Firenze, Italy) and to a respiratory effort system (thoracic respiratory
transducer, Bionen S.a.S., Firenze, Italy). EEG recording started
when electrode placement was completed, and the total recording
time was 20 min, including calibration and the initial impedance
check. The EEG data were stored in the acquisition station (Halley
Galileo, EBNeuro, Firenze, Italy) for later analysis.
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Genome-wide association analysis and fine-mapping
To map the epilepsy locus, 40 cases and 44 controls were
genotyped using the Affymetrix Canine Genome 2.0 Array
platinum set (Affymetrix, Santa Clara, CA, USA) containing
49,663 SNP markers. The genotyping was performed as a part of
the LUPA project at the Centre National de Ge´notypage, Paris,
France. The case-control association analysis was performed with
PLINK v1.07 [63] with the criteria of MAF ,0.05, call rate
.75% and ,25% of missing genotypes in individual dogs. After
applying these filters 43,378 SNPs remained in the analysis for all
dogs. Genome-wide significance was ascertained through 100 000
random permutations of the epilepsy phenotype. The genomic
inflation factor for the population was 1.13 and the association p-
values were adjusted for it.
Fine mapping and replication was performed with 96 selected
SNPs from a 8.3 Mb region (12,660,614–20,989,289 bp) on
CFA37. The SNP density was 1 SNP/100 Kb. All base pair
positions mentioned in this article are based on CanFam 2.0.
Genotyping was performed using the Sequenom (San Diego, CA,
USA) iPLEX methodology at the Centre of Integrated Genomic
Medical Research, University of Manchester, UK. A total of 201
samples were genotyped including samples from Finland (54 cases,
63 controls) Denmark (32 cases, 28 controls), Sweden (11 cases and
13 controls) and Middle Europe. After quality control (MAF
,0.05, SNP call rate .0.75, individual call rate .0.75), a total of
58 SNPs and 83 cases and 99 controls were included in the
association analysis with PLINK v1.07 using a single-marker
association analysis and haplotype sliding window analysis with 3–
5 markers at a time [63].
To confirm the nominal associations in the other chromosomes
single SNPs on chromosomes 3 (BICF2P397912 at 82,766,251 bp),
4 (TIGRP2P58276 at 13,088,720 bp), 9 (BICF2P1288768 at
18,597,315 bp), 18 (TIGRP2P239410 at 15,846,321 bp) and 23
(BICF2G630382382 at 22,138,085 bp) were genotyped in 54
Belgian Shepherd cases and 62 controls in addition to the samples
genotyped in the GWAS. The genotyping was performed using
Custom Taqman SNP Genotyping Assays (Applied Biosystems by
Life Technologies Corporation, Carlsbad, CA, USA). The poly-
merase chain reactions were performed according to the standard
protocol provided by the manufacturer in 10 ml reaction volume,
and run and analyzed using the Applied Biosystems 7500 Fast Real-
Time PCR System (Foster City, CA, USA). The SNP genotype data
was analyzed for association using PLINK v1.07 [63]. All the
markers were in HWE (p.0.05) and the genotyping call rates
ranged from 96–100%.
Association in other breeds
A SNP located at 18,123,961 bp (BICF2P890779) on CFA37
was screened in 8 other breeds with epilepsy including Lagotto
Romagnolo (23 cases, 23 controls), Miniature Pinscher (22 cases,
20 controls), Kromfohrla¨nder (34 cases, 20 controls), Whippet
(24 cases, 26 controls), Border Terrier (42 cases, 20 controls),
Schipperke (63 cases, 48 controls), Finnish Spitz (62 cases,
81controls) and Finnish Lapphund (44 cases, 60 controls). The
genotyping was performed using Custom Taqman SNP Genotyp-
ing Assays (Applied Biosystems by Life Technologies Corporation,
Carlsbad, CA, USA) according to the standard protocol provided
by the manufacturer in 4 ml reaction volume, and run and
analyzed using the Applied Biosystems 7900HT Fast Real-Time
PCR System (Foster City, CA, USA). The SNP genotype data was
analyzed for association using PLINK v1.07. The genotyping call
rates within breeds ranged from 91–100%, and there was no
deviation from HWE in any of the breeds (p.0.05).
Sequencing and mutation analysis
Exons and splice junctions were amplified by PCR with ADAM23-
specific primers available upon request. The PCR products were
purified with ExoSAP-IT kit (USB Corporation, Cleveland, Ohio)
and sequenced with an ABI Prism 3730xl DNA analyzer (Applied
Biosystems, Foster City, CA). The exon 12 variant (R387H) was
sequenced in 155 BS cases and 111 controls and in three epileptic
dogs in 38 other breeds. Pathogenicity of the mutation was predicted
by programs Panther [64] and PolyPhen-2 [65].
Gene expression analysis
Expression level of ADAM23 was analyzed in three healthy
Belgian Shepherds and three Belgian Shepherds with epilepsy.
Samples from cortex cerebrum and cerebellum were taken
immediately after euthanasia and snap-frozen in liquid nitrogen.
Messenger RNA extraction, cDNA synthesis and quantitative PCR
were performed as previously described [66]. RNA quality was
ascertained and the RQI number determined by analysis on an
Experion System (Bio-Rad, Hercules, CA, USA). Two primer sets
for qPCR were designed; set 1: forward primer 59-CCTGGCA-
GATGAAGACAACA, reverse primer 59- GAGCCAAAGGCTT-
CAATCTG; set 2: forward primer 59- AGCCACCTGCATC-
TGTGATT, reverse primer 59- GTGCCCCCAAGGACAATAG.
The gene RPL4 was used as a reference gene in the expression level
analysis. Expression data were analyzed using REST v2.0.7 [67].
Supporting Information
Table S1 Summary of the clinical features of 94 epileptic
Belgian Shepherds collected through the owner-filled epilepsy
questionnaires.
(XLS)
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